BizJournals Portfolio
Dec 09 2009 9:37am EDT

Dendreon Raises Cash

TechFlash reports: Dendreon is looking to turn on the marketing and production engines in advance of the launch of its prostate cancer treatment, Provenge. The company said today that it plans to sell 15 million shares of common stock, with proceeds from the stock sale being used to build out new facilities in Atlanta and Orange County, California, as well its existing facility in Morris Plains, New Jersey.

The Seattle biotech didn't disclose the price of the stock sale, which Dow Jones reports will increase outstanding shares by some 13 percent. But Luke Timmerman at Xconomy reports that the stock sale—based on a 5 percent discount of today's closing stock price of $26.64—could easily raise $400 million.

Dendreon is looking to begin selling its prostate drug, Provenge, after gaining FDA approval. And the company has talked before about its ambitious plans for manufacturing plants.

The stock has soared this year, up 481 percent to date as investors await the FDA approval.


John Cook is executive editor of the Puget Sound Business Journal's TechFlash blog.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.


Connect With Portfolio.com

Come on, like us—you know you want to.

Follow us and if you're an innovative entrepreneur, we'll return the favor.

Today's top stories, conversation starters, and the back nine business bites.

spotlight on

People & Ideas

Whisky To-Go-Go

Now there's a company that let's you taste your knowledge of fine blended Scotches by mixing a whisky of your own. Read More